Premium
P4‐092: SLEEP DISORDERED BREATHING IN THE ELDERLY AND RISK FOR ALZHEIMER'S DISEASE USING FDG‐PET
Author(s) -
Gumb Tyler,
Mantua Janna,
Li Yi,
Osorio Ricardo
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1607
Subject(s) - medicine , sleep disordered breathing , cardiology , disease , cognitive impairment , positron emission tomography , nuclear medicine , audiology , obstructive sleep apnea
innovation fund on AD. Investigators will develop and make available common methodological tools and platforms, which will vastly increase Quebec researchers’ ability to contribute in a highly innovative fashion to acquisition of new knowledge in the field of AD. Specific objectives are to: 1) validate cognitive/clinical tests; 2) develop a standardized ’toolbox’ combining biological, neuroimaging and cognitive markers; 3) identify novel AD-related molecular mechanisms; 4) identify disease progression-impacting lifestyle protective factors; and 5) implement clinical procedures allowing earlier and more accurate diagnosis of AD. All CIMA-Q data will be available to the research community.Methods: Four thematic groups (Cognitive/neuropsychiatric markers, Neuroimaging, Risk and protection factors, Therapeutic targets and biomarkers) will develop and use harmonized evaluation procedures for data collection. One hundred and fifty subjective memory impairment, 100 mild cognitive impairment, 50 AD dementia, 50 healthy older and 20 younger individuals will be recruited from five memory clinics and the NuAge cohort (a population-based cohort of 1,793 older adults). Participants will be characterized with clinical, cognitive and neuroimaging measures. Furthermore, a biobank of stem cell lines, cerebrospinal fluid, DNA/RNA, plasma/serum and progressively available autopsied brains will be established from these well-characterized subjects to identify pathological profiles, novel therapeutic targets and biomarkers. An established data management system (LORIS) will be used to store data and assist in subsequent queries and data analysis. Results: Management policies and standardization/quality control procedures have been established. Operationalization of recruitment, data and biospecimen collection is currently under way. Subject recruitment is expected to start in the spring of 2014. Conclusions: The collaborative framework of CIMA-Q, federating more than 70 researchers from seven Quebec universities, will significantly increase high-impact pluridisciplinary research and productivity in the field of cognitive decline and AD. It will also increase opportunities for state of the art collaborative international research.